What Xigris Treats: Main Uses and Benefits

This medication is considered relevant within the Intensive Care Medicine domain for adult patients experiencing severe sepsis who are identified as patients experiencing severe, acute physiological stress. It was applied in clinical settings that involve acute or unstable symptom patterns associated with conditions associated with heightened physiological stress. The treatment may assist with managing the resulting physiological strain, contributing to support general well-being during these critical states.

Drotrecogin alfa was relevant in conditions characterized by periods of heightened symptoms associated with severe physiological stress. It was primarily used in situations involving severe, acute physiological stress, which involves conditions involving functional stability becoming affected, such as cardiovascular and respiratory function. It was used to help address symptom clusters related to uncontrolled systemic imbalance.

“By supporting the patient's stability when symptoms become temporarily overwhelming, the medication assists with maintaining functional stability.”

---

Quick Fact: Supportive Management for Systemic Imbalance

The core therapeutic relevance of Drotrecogin alfa (Xigris) lies in its application in conditions involving inflammatory or irritative processes where the body's response leads to symptoms linked to organ-specific functional stress and functional strain. It supports the patient during difficult episodes by easing distress and helps maintain a sense of stability when symptoms are more noticeable in a critical care setting.

Eligibility Map: Who can and cannot use Xigris (Drotrecogin Alfa) — Official Regulatory Information

---

Eligibility Scope

Populations for whom use is allowed (as stated in label):

• Adult patients (≥18 years) with severe sepsis who have a high risk of death (e.g., as determined by an APACHE II score ≥25).

Populations for whom use is not recommended (if applicable):

• Adult patients with severe sepsis and a lower risk of death (e.g., APACHE II score <25)—the medicine is not indicated for this group.
• The medicine is not approved for patients with single organ dysfunction who have had recent surgery (within 30 days).

Populations for whom use is contraindicated:

• Active internal bleeding, recent hemorrhagic stroke (within 3 months), recent intracranial or intraspinal surgery (within 2 months), or severe head trauma requiring hospitalization.
• Patients with a known bleeding diathesis, chronic severe hepatic disease, or a platelet count <30,000 x 10⁶/L.
• Patients with concurrent therapeutic heparin dose ≥15 International Units/kg/hr or a known hypersensitivity to the drug.

---

Age-Related Eligibility Rules

• The medicine is contraindicated in all pediatric patients (below 18 years) as safety and effectiveness have not been established.
• Geriatric patients (≥65 years) showed no overall differences in safety or effectiveness when compared to younger adults in clinical studies.

Eligibility-Related Restrictions

• Use requires careful risk assessment for patients with recent use of oral anticoagulants, platelet inhibitors, or a recent ischemic stroke (within 3 months).

---

Connection to the overall eligibility profile

Regulatory documents define who can and cannot use the medicine by strictly limiting its use to a high-risk subgroup of adult patients with severe sepsis, while establishing an extensive list of absolute contraindications primarily focused on eliminating individuals with a pre-existing high risk of hemorrhage. Furthermore, official labeling explicitly designates the medicine as contraindicated and not established for use in the entire pediatric population.

Xigris Interactions with other medicines and products

Interaction Scope and Mechanistic Basis

The official interaction profile for Drotrecogin alfa (activated) is based on its pharmacodynamic effect on the body's natural blood-clotting system (hemostasis). Regulatory documents confirm that studies examining metabolic interactions, such as those mediated by CYP enzymes or drug transporters, were not performed in the patient population. Therefore, all documented interactions pertain to additive pharmacological risk and laboratory assay interference.

Formal Restrictions and Interacting Substances

The most stringent documented restriction is the contraindication for co-administration with concurrent therapeutic heparin therapy at doses of 15 International Units/kg/hr or higher. Caution must be employed when the product is co-administered with other medicinal products that affect hemostasis, including thrombolytics, oral anticoagulants (e.g., warfarin), hirudins, and various antiplatelet agents (e.g., aspirin, NSAIDs). Prophylactic low-dose heparin may generally be co-administered without required dosage adjustment.

Timing Constraints and Assay Interference

Administration is subject to mandatory timing rules for procedures: the product must be discontinued 2 hours prior to any major invasive procedure or surgery. Administration may restart 12 hours after the procedure, provided adequate hemostasis has been secured. The product interferes with specific laboratory tests by causing variable prolongation of the Activated Partial Thromboplastin Time (APTT), which prevents the APTT from being reliably used to assess the product’s effect.

How Xigris Works

Targeting Coagulation and Fibrinolysis

This drug is a form of activated Protein C (APC) that functions as an enzyme to inactivate key procoagulant cofactors, Factor Va and VIIIa, within the blood clotting cascade.

By inhibiting these factors, the mechanism restricts thrombin generation and subsequent fibrin formation. Concurrently, its neutralization of PAI-1 (Plasminogen Activator Inhibitor-1) increases fibrinolytic activity. The combined effect is a reduction in microvascular clot formation and enhanced capacity for clot lysis.

Modulating Vascular and Cellular Inflammation

The drug also engages the Endothelial Protein C Receptor ( EPCR) on blood vessel surfaces to exert distinct anti-inflammatory effects. This action dampens specific pro-inflammatory signaling pathways like NF-kappa B and limits the release of certain cytokines, thereby reducing the adherence of immune cells to the vessel walls. This consequence results in reduced cell surface permeability and mitigated endothelial damage that arises from activated inflammatory pathways.

How Xigris (Drotrecogin Alfa) is Used

Xigris (Drotrecogin alfa (activated)) is a specialized therapeutic protein that is administered solely through a continuous intravenous (IV) infusion in a highly controlled environment, such as a hospital's Intensive Care Unit (ICU). Its usage is governed by standardized protocols and is not intended for outpatient use.

---

Administration Principles and Dosing Regimen

The standard administration regimen is a single, continuous infusion lasting 96 hours (four days). The rate of infusion is fixed at 24 mu g/kg/hr (micrograms per kilogram per hour), which is calculated based on the patient’s actual body weight.

Guidelines mandate that the medication must be delivered using an infusion pump for precise rate control and requires a dedicated intravenous line or a dedicated lumen of a multilumen catheter. Bolus doses or dose escalations are not part of the standard usage protocol.

---

Preparation, Duration, and Population Rules

The medicine is supplied as a lyophilized powder and requires specific preparation steps before administration, involving initial reconstitution with sterile water, followed by subsequent dilution with 0.9% Sodium Chloride Injection.

If the infusion is interrupted for procedural reasons, it must be restarted immediately at the same prescribed rate to complete the full 96-hour duration, as the safety and efficacy of administering more than one course have not been established. No dose adjustments are required for older adults or for adult patients based on renal or hepatic function. However, the use of Xigris is not recommended in pediatric patients under 18 years of age.

Xigris: Clinical Evidence and Withdrawal

Xigris (drotrecogin alfa [activated]) was a recombinant form of human Activated Protein C (APC), a protein approved for the treatment of severe sepsis in adult patients considered to be at high risk of death, often associated with multiple organ failure.

---

Pivotal and Conflicting Trial Data

Initial approval was primarily based on the PROWESS (Protein C Worldwide Evaluation in Severe Sepsis) trial. This Phase 3 study, which was terminated early for efficacy, suggested an absolute reduction in 28-day mortality in patients receiving the drug compared to placebo. The drug was associated with an increased risk of serious bleeding events.

Due to lingering questions regarding the drug’s benefit and consistency of findings, subsequent clinical investigations were performed:

• ADDRESS Trial (Adults with low risk of death): This study in patients with less severe sepsis (low risk of death) found no evidence of survival benefit.
• PROWESS-SHOCK Trial: This large, placebo-controlled trial, mandated by European regulators, was designed to confirm the benefit-risk profile in patients with septic shock. This study failed to meet its primary endpoint of a statistically significant reduction in 28-day all-cause mortality.

---

Market Withdrawal

Following the results of the PROWESS-SHOCK trial, which did not demonstrate a survival benefit, the manufacturer voluntarily withdrew Xigris from the market worldwide in 2011. Regulatory bodies, including the U.S. FDA and the European Medicines Agency (EMA), subsequently informed healthcare professionals not to initiate or continue treatment with the drug.

Common questions about Xigris (FAQ)

Q: Is Xigris still being used in hospitals today?

The drug Xigris was voluntarily withdrawn from the global market by its manufacturer in 2011. Following this withdrawal, regulatory agencies like the FDA and EMA advised healthcare professionals not to start or continue treatment with Xigris. This indicates the drug is no longer an option for use in hospitals.

Q: Why did the manufacturer voluntarily withdraw Xigris from the global market?

The manufacturer’s decision to withdraw the drug followed the results of the PROWESS-SHOCK trial. This study failed to achieve its main goal of demonstrating a statistically significant reduction in death rates. Official information states this led to a reevaluation of the drug's overall benefit-risk profile.

Q: Is the increased risk of bleeding from Xigris limited to only the time of infusion?

The official product information indicates that the most significant adverse effect, the increased risk of serious bleeding, was noted to occur primarily during the infusion period, which lasts the first 96 hours. The drug is rapidly cleared from the bloodstream, with measurable levels dropping below detectability within about two hours after the infusion is stopped.

Q: Can Xigris cause severe allergic or anaphylactic reactions?

Official regulatory documents acknowledge that allergic or anaphylactic reactions are documented as potential adverse events. If such a reaction were to occur during treatment, regulatory guidance states the infusion should be immediately discontinued and appropriate therapy may be initiated.

Q: Is it necessary to stop antiplatelet medicines before receiving Xigris?

Official guidance states that caution must be used when Xigris is given alongside other medications that affect blood clotting, including antiplatelet drugs like aspirin. However, these medications are not universally contraindicated for use with Xigris. An exception is required if a major invasive procedure is planned, where the drug must be discontinued beforehand.

Q: Can Xigris be stopped and then restarted if a procedure is needed?

If the infusion is interrupted for any reason, regulatory documents note that the infusion should be restarted immediately to ensure the full 96-hour duration is completed. For procedures that carry a risk of bleeding, official documents mandate that Xigris must be discontinued two hours prior and can only be restarted 12 hours after the procedure, provided any bleeding has been controlled.

Q: Did the clinical trials show Xigris only provided a benefit to the most severely ill patient groups during the initial studies?

Studies indicated that the survival benefit of Xigris was not established in adult patients with less severe sepsis, defined as those with a lower risk of death (e.g., an APACHE II score below 25). The mortality difference that led to initial approval was observed primarily in the group of patients who were considered to be at a high risk of death (APACHE II score of 25 or higher).

Q: Why were later clinical trials, like PROWESS-SHOCK, conducted for Xigris?

The PROWESS-SHOCK study was initiated because European regulators required the manufacturer to confirm the drug’s benefit-risk profile after initial trial results raised questions about its effectiveness and consistency. It was designed to address these lingering questions and was a condition for the drug to remain on the market in Europe.

Q: What is the difference between Xigris and a standard antibiotic for sepsis?

Xigris is fundamentally different from a standard antibiotic. Xigris is classified as an Antithrombotic Agent and a Serine Protease, which is a type of therapeutic protein. Its function is to modulate the body’s life-threatening response to the infection by reducing excessive blood clotting and inflammation. In contrast, an antibiotic is a drug used to directly kill or inhibit the growth of the bacteria causing the infection.

Q: Is Xigris approved for use in pediatric (child) patients?

Official regulatory information clearly states that Xigris is not indicated for use in children and adolescents (those under 18 years of age). The safety and effectiveness of the drug have not been established in the pediatric population. Due to safety concerns, it is explicitly listed as contraindicated for use in children.

Q: Is the drug's withdrawal related to new advances in the standard of care for sepsis?

The manufacturer noted that advances in the standard of care for severe sepsis over the preceding ten years could be a contributing factor to the PROWESS-SHOCK study’s findings. This factor was cited alongside the trial’s primary result as part of the re-evaluation of the drug's role.

Q: How quickly must Xigris treatment be started after the onset of organ failure?

Regulatory information indicates that use of Xigris should mainly be considered when treatment can be started within 24 hours after the onset of organ failure. Clinical trials generally aimed to initiate the infusion within 48 hours of diagnosis.

Q: What is the maximum duration for a single infusion bag of Xigris?

The prepared intravenous solution is stable only for a short time. Official prescribing information states that the maximum duration of infusion from a single prepared bag or syringe is 12 hours. Because the full course of treatment lasts 96 hours, multiple preparations were required during administration.

Q: Does Xigris interact with therapeutic heparin only at a specific high dose?

Official labeling establishes a strict contraindication (absolute restriction) against using Xigris concurrently with therapeutic heparin doses of 15 International Units/kg/hr or higher. However, regulatory documents note that prophylactic (preventative) low-dose heparin was generally used in clinical trials with no required dosage adjustment.

Q: What is known about the development of antibodies to the drug component of Xigris?

Studies on Xigris found that the formation of anti-Activated Protein C antibodies was generally uncommon, occurring in less than 1% of patients treated. Furthermore, regulatory research indicated there was no evidence that these antibodies were capable of neutralizing the drug’s intended effect on blood parameters.

The storage and disposal of Xigris (drotrecogin alfa (activated)) is governed by strict regulatory constraints to maintain the stability of this biologic product.

Storage Conditions

The unreconstituted vials must be stored in a refrigerator at a temperature between 2°C and 8°C (36°F and 46°F) and must not be frozen.

The vials require protection from light and must remain in the original carton until use. The medicine must be kept out of the sight and reach of children.

Solution Stability and Handling

Once reconstituted and diluted, the final intravenous solution has a strict total time limit for use of 24 hours. Exposure of the solutions to heat or direct sunlight must be avoided, and vigorous agitation during preparation is prohibited.

Disposal

Due to the voluntary market withdrawal, all unused or expired product must be returned to the supplier. Xigris must not be disposed of in household waste or wastewater; disposal of any remaining materials must follow local regulatory pharmaceutical waste requirements.